EUVIMEDEUVIMED entdecken
Crossref

Efectividad de tixagevimab/cilgavimab en la reducción de la infección, ingresos hospitalarios y mortalidad por SARS-CoV-2 en pacientes inmunodeprimidos

Marc Marti-Pastor, Ricardo Bou-Monterde, Lucia Ciancotti-Oliver, Marta Alcover-Pons, Aurora Amorós Cantero, Raquel Sánchez-Lopezosa, Neus Montañana-Rosell

Medicina Clínica · 2024

DOI: 10.1016/j.medcli.2024.03.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina Clínica, 2024. Verfasst von Marc Marti-Pastor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Medicina Preventiva y Salud Pública. Hospital Universitario de la Ribera, Valencia, España. Electronic address: mmartip27@gmail.com. Hauptthemen laut MEDLINE: Hospitalization, Immunocompromised Host, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Inmunocompromised people have higher SARS-CoV-2 morbi-mortality and they are subsidiary to receive pre-exposure prophylaxis. The objective of this study is to evaluate the effectiveness of tixagevimab/cilgavimab (Evusheld) in preventing SARS-CoV-2 infections, hospitalizations and mortality in immunocompromised patients. MATERIALS AND METHODS: 119 immunocompromised people>18 years old eligible of receiving Evusheld were followed for 6 months. People with previous SARS-CoV-2 infection or incomplete vaccination regimen were exluded. A total of 19 people who received Evusheld were matched by propensity score, using a 1:1 ratio, with another 19 people who did not receive Evusheld. Sociodemographic, related to SARS-CoV-2 risk factors and related to immunosuppression variables were included. The dependent variables were infection, hospitalization, and mortality related to SARS-CoV-2. Statistical analyzes were performed using SPSS Statistics 19.0, STATA 11.0, and the R statistical package. RESULTS: In total, 4 people in the Evusheld group and 11 in the control group had SARS-CoV-2 infection, showing an incidence rate of 3.87 and 13.62 per 100 person-months, respectively. The HR (Hazard Ratio) was 0.29 (95% CI=0.09-0.90) for SARS-CoV-2 infection, 0.37 (0.07-1.92) for SARS-CoV-2 hospitalization and, 0.23 (0.03-2.09) for SARS-CoV-2 mortality in the Evusheld group compared to control group. CONCLUSIONS: This study demonstrates that Evusheld reduces the SARS-CoV-2 infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationImmunocompromised HostCOVID-19HumansMaleFemaleMiddle AgedAgedAdultAntibodies, Monoclonal, HumanizedAntiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Propensity Score

Stichwörter der Autor:innen

CilgavimabCoronavirus 2 productor del síndrome agudo respiratorio grave (SARS-CoV-2)EfectividadEffectivenessHospitalizacionesHospitalizationsMortalidadMortalitySARS-CoV-2Tixagevimab

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral Agents

Autor:innen und Institutionen

  • Servicio de Medicina Preventiva y Salud Pública. Hospital Universitario de la Ribera, Valencia, España. Electronic address: mmartip27@gmail.com.
  • Servicio de Medicina Preventiva y Salud Pública. Hospital Universitario de la Ribera, Valencia, España.
  • Servicio de Medicina Interna. Hospital Universitario de la Ribera, Valencia, España.

Zitieren

APA

Marti-Pastor, M., Bou-Monterde, R., Ciancotti-Oliver, L., Alcover-Pons, M., Amorós Cantero, A., Sánchez-Lopezosa, R., & Montañana-Rosell, N. (2024). Efectividad de tixagevimab/cilgavimab en la reducción de la infección, ingresos hospitalarios y mortalidad por SARS-CoV-2 en pacientes inmunodeprimidos. Medicina Clínica. https://doi.org/10.1016/j.medcli.2024.03.013

Vancouver

Marti-Pastor M, Bou-Monterde R, Ciancotti-Oliver L, Alcover-Pons M, Amorós Cantero A, Sánchez-Lopezosa R, et al. Efectividad de tixagevimab/cilgavimab en la reducción de la infección, ingresos hospitalarios y mortalidad por SARS-CoV-2 en pacientes inmunodeprimidos. Medicina Clínica. 2024. doi:10.1016/j.medcli.2024.03.013

BibTeX
@article{MartiPastor2024,
  author = {Marti-Pastor, Marc and Bou-Monterde, Ricardo and Ciancotti-Oliver, Lucia and Alcover-Pons, Marta and Amorós Cantero, Aurora and Sánchez-Lopezosa, Raquel and Montañana-Rosell, Neus},
  title = {Efectividad de tixagevimab/cilgavimab en la reducción de la infección, ingresos hospitalarios y mortalidad por SARS-CoV-2 en pacientes inmunodeprimidos},
  journal = {Medicina Clínica},
  year = {2024},
  doi = {10.1016/j.medcli.2024.03.013}
}
Kostenlos starten →